Natural products have been identified as ligands for a number of members of the nuclear hormone receptor (NHR) superfamily. Often these natural products are used as dietary supplements to treat myriad ailments ranging from perimenopausal hot flashes to hypercholesterolemia and reduced cognitive function. Examples of some natural product ligands for NHRs include genestein (estrogen receptors NR3A1 and NR3A2), guggulsterone (farnesoid X receptor NR1H4), and St. John's wort (pregnane X receptor, NR1I2). In this study, we identified the first nonoxysterol natural product that functions as a ligand for the liver X receptor (LXR␣ and LXR␤; NR1H3, NR1H2), a NHR that acts as the receptor for oxysterols and plays a key role in regulation of cholesterol metabolism and transport as well as glucose metabolism. We show that paxilline, a fungal metabolite, is an efficacious agonist of both LXR␣ and LXR␤ in biochemical and in vitro cell-based assays. Paxilline binds directly to both receptors and is an activator of LXR-dependent transcription in cell-based reporter assays. We also demonstrate that paxilline binding to the receptors results in efficient activation of transcription of two physiological LXR target genes, ABCA1 and SREBP. The discovery of paxilline, the first reported nonoxysterol natural product ligand of the LXRs, may provide insight into the mechanism of ligand recognition by these receptors and reaffirms the utility of examining natural product libraries for identifying novel NHR ligands.
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Natural products are proven sources of biologically active molecules that have played a critical role in pharmacology. Many of these natural products have been demonstrated to be useful for medicinal purposes. A limited number of natural products appear to act as ligands of nuclear hormone receptors. One of the most well characterized natural product nuclear receptor ligands is genestein, a product of soy, which binds directly to estrogen receptors (NR3A1 and NR3A2) and is used as a dietary supplement to alleviate menopausal symptoms in women (Kuiper et al., 1998; Tham et al., 1998) . Interestingly, genestein has been recently shown to also function as a low-affinity ligand for yet another nuclear receptor, peroxisome proliferator-activated receptor ␥ (NR1C3) (Dang et al., 2003) . A related isoflavone soy product also used in dietary supplements, daidzein, is another estrogen receptor agonist, albeit weaker than genestein (Wiseman, 2000) . The active compound within St. John's wort, an herbal remedy for depression, is a potent agonist of the xenobiotic nuclear receptor, pregnane X receptor (PXR, NR1I2) (Moore et al., 2000; Watkins et al., 2003) . Although the antidepressent activity of St. John's wort does not appear to be mediated by its PXR activity, the induction of cytochrome P450 (CYP) 3A4 is mediated by activation of this receptor potentially leading to a significant increase in the metabolism of a variety of drugs taken by individuals using this supplement (Moore et al., 2000) . The most recent report of a natural product ligand of a nuclear receptor is the discovery that guggulsterone, found in the resin of the guggul tree, is an efficacious antagonist of the farnesoid X receptor (FXR, NR1H4), the bile acid receptor (Urizar et al., 2002; Wu et al., 2002) . Guggul tree extract has been suggested to lower low-density lipoprotein levels in animal models, has been successfully used in Ayurveda medicine to treat obesity and lipid disorders, and a modern antihyperlipoproteinemic drug based on the actions of guggulsterone is marketed in India (Satyavati, 1988; Singh et al., 1990; Dev, 1997) . Beyond the use of natural products directly as dietary supplements, identification of novel natural product ligands for a given receptor often provides pharmacological tools and unique insight into drug design.
The liver X receptors [LXR␣ (NR1H3) and LXR␤ (NR1H2)] are additional members of the nuclear receptor superfamily and were originally identified as orphan receptors (Shinar et al., 1994; Song et al., 1994; Seol et al., 1995; Teboul et al., 1995; Willy et al., 1995) . Subsequently, oxysterol cholesterol metabolites were demonstrated to be physiological ligands for LXR (Janowski et al., 1996) . These two receptors play a key role in the regulation of cholesterol metabolism and transport as well as glucose metabolism and inflammation Cao et al., 2003; Joseph et al., 2003) . Modulation of the activity of these receptors may be useful in the treatment of a number of pathophysiological states including dyslipidemia, atherosclerosis, and diabetes Tangirala et al., 2002; Cao et al., 2003) .
In this study, we describe the discovery of the first nonoxysterol natural product ligand of LXR. The indole alkoid fungal metabolite from Penicillium paxilli, paxilline, functions as a ligand for both LXR␣ and LXR␤. Paxilline binds directly to both receptors leading to recruitment of coactivators and activates the receptors in a cell-based context. In addition, paxilline efficaciously induces the expression of LXR target genes, ABCA1 and SREBP. Our data confirm that natural product libraries are a rich source of ligands for nuclear receptors and may provide pharmacological agents for investigation of the function of these receptors as well as potential drugs. Radioligand Binding Assay. The LXR radioligand binding assay was performed using scintillation proximity technology as previously described (Thomas et al., 2003) . We used 800 ng of baculovirus-expressed, His-tagged LXR␣-LBD protein (amino acids 162-447) or 600 ng of LXR␤-LBD protein (amino acids 202-461), 25 nM 3 H-labeled 25-hydroxycholesterol (Amersham Biosciences, Inc., Piscataway, NJ), 0.05 mg of yttrium silicate polylysine-coated SPA beads (Amersham Biosciences, Inc.), and varying concentrations of competitor per well of a 96-well OptiPlate (PerkinElmer Life Sciences, Boston, MA). Protein, radioligand, and competitor were added to the plate. SPA beads were then added to the assay plate followed by 10 min of gentle shaking at room temperature and protected from light. The plates were incubated in the dark at room temperature for 2 h before reading in a TopCount plate reader (PerkinElmer Life Sciences).
Materials and Methods
Coactivator Interaction Assay. Interaction between LXR␣/ LXR␤ and the coactivators SRC-1 or TIF-2 were assayed using AlphaScreen (amplified luminescent proximity homogenous assay) technology (PerkinElmer Life Sciences). The assay was performed in white, low volume, 384-well plates using a final volume of 15 l containing final concentrations of 20 nM His-tagged baculovirus expressed LXR␣-LBD or LXR␤-LBD protein, 5 nM GST-TIF-2 or GST-SRC-1 protein that contained the entire nuclear receptor interacting domain of the coactivator protein fused to GST and 10 g/ml of both Ni 2ϩ chelate donor beads and anti-GST acceptor beads (PerkinElmer Life Sciences). The assay buffer contained 25 mM HEPES (pH 7.0), 100 mM NaCl, 0.1% bovine serum albumin, and 2 mM dithiothreitol. All manipulations involving assay beads were done in ambient light. Assay plates were covered with a clear seal and incubated in the dark for 2 h after which the plates were read for 1 s per well in a PerkinElmer fusion microplate analyzer using the manufacturers standard AlphaScreen detection protocol.
Cell Culture and Transfections. HEK293 cells were cultured in 3:1 DMEM/F-12 containing 10% fetal bovine serum and supplemented with 1% penicillin and streptomycin, 1% L-glutamine, and 20 mM HEPES. Cells were seeded 48 h before transfection at 6 ϫ 10 6 cells/T225 flask in 30 ml of growth medium. Cells were transfected with Fugene transfection reagent (Roche Diagnostics, Indianapolis, IN) according to the Fugene protocol with 330 ng of pcDNA3-hRXR-␣, 33 ng of pCMV6 LXR␣ or LXR␤, 660 ng of pGL3B-E1b-3XLXRE luc (Thomas et al., 2003) , and 10 l of Fugene per 10 6 cells. Growth medium was replaced during transfection with 3:1 DMEM/F-12 containing 10% charcoal/ dextran-treated, heat-inactivated fetal bovine serum and supplemented with 1% penicillin and streptomycin, 1% L-glutamine, and 20 mM HEPES. After 24 h, cells were harvested and plated into 96-well white plates at 50,000 cells per well in 90 l of complete transfection medium, allowed to attach for 2 h, then treated with 10 l of 10ϫ compound and dimethyl sulfoxide controls. After 24 h, cells were lysed and assayed for luciferase activity.
ABCA1 mRNA Quantitation. ABCA1 mRNA expression was measured in THP-1 macrophage cells using a bDNA assay (QuantiGene high volume kit; Bayer Corp.-Diagnostics Div., Tarrytown, NY). THP-1 cells were grown in suspension at 37°C 5%/95% CO 2 /air incubator in growth medium (RPMI 1640 medium containing 0.05 mM 2-mercaptoethanol and 10% fetal bovine serum at a density of 250,000 cells per milliliter and allowed to reach a density of 1 million cells per milliliter. Growth medium was then changed to growth medium containing 10 nM phorphol 12-myristate 13-acetate and cells were plated in 96-well dishes at a density of 100,000 cells per well. After an overnight incubation, medium was changed to a growth medium containing 10% lipoprotein depleted fetal bovine serum. Cells were treated with various concentrations of compounds serially diluted to obtain a 10-point concentration curve from a final concentration of 20 to 0.001 M. After a 24-h incubation with compound, cells were lysed using 50 l/well bDNA assay kit lysis reagent. The kit reagents as well as ABCA1-specific primer sets were used to process the samples for the bDNA assay as previously described . After a 15-min incubation at 37°C, 100 l of the lysis buffer from each well were transferred to the corresponding wells of the capture plate. The capture plate was incubated overnight at 53°C. The capture plate was then washed twice with QuantiGene wash buffer followed by the addition of 100 l/well QuantiGene amplifier working reagent. The plate was incubated for 60 min at 46°C followed by two washes. The mRNA to be measured was then labeled by the addition of 100 l of QuantiGene label probe working buffer followed by a 60-min incubation at 46°C. The capture plate was then washed twice followed by the addition of 100 l/well QuantiGene substrate plus QuantiGene enhancer reagent. The plates were incubated at 37°C for up to 30 min and then read on a luminometer to detect the luminescent signal. The induction of ABCA1 mRNA expression was calculated as a ratio of compoundtreated luminescent levels compared with untreated control levels. SRE Assay and SREBP mRNA Quantitation. As previously described (Thomas et al., 2003) , HepG2 cells stably transfected with a 3XSRE thymidine kinase luciferase reporter construct were treated for 24 h with an LXR ligand to assess SREBP activity. SREBP mRNA was quantitated by Taqman real-time polymerase chain reaction as previously described (Thomas et al., 2003) .
Data Analysis. Dose responses and displacement curves were analyzed in GraphPad Prism (GraphPad Software Inc., San Diego, CA) allowing calculation of both EC 50 and K i values. Each point of data represents minimal triplicate wells, and the results shown are representative of at least three independent experiments.
Results
A screen of a natural product library for compounds with the ability to modulate the activity of LXR yielded the iden-292 tification of the first nonoxysterol natural product ligand for this receptor, paxilline. Paxilline is an indole alkoid metabolite from the fungus, P. paxilli. The structure of paxilline is shown in Fig. 1 and compared with several LXR ligands including a natural ligand, 22(R)-hydroxycholesterol, as well as synthetic ligands GW3965, T0901317, and APD Schultz et al., 2000; Collins et al., 2002; Sparrow et al., 2002) .
We examined the ability of paxilline to bind directly to both LXR␣ and LXR␤ using a radioligand binding assay. A scintillation proximity assay format was employed using tritiated 25-hydroxycholesterol as the radioligand. As illustrated in Fig. 2 , paxilline displaced 25-hydroxycholesterol from both receptors (LXR␣ K i ϭ 660 nM; LXR␤ K i ϭ 1,100 nM). In contrast a natural oxysterol ligand, 22(R)-hydroxycholesterol [22(R)-OHC] displayed higher affinity in this assay (LXR␣ K i ϭ 250 nM; LXR␤ K i ϭ 490 nM) (Fig. 2) . Paxilline did not bind and/or activate any other nuclear receptor examined (IC 50 and/or EC 50 Ͼ10 M for ER␣, ER␤, TR, RXR, FXR) (data not shown). Paxilline also induced LXR recruitment of both coactivators SRC-1 or TIF-2 in a cell-free AlphaScreen assay system (Fig. 3) . Using purified recombinant LXR␣ or LXR␤ and purified GST-SRC-1 or GST-TIF-2, we demonstrated that increasing amounts of paxilline resulted in dose-dependent recruitment of these coactivators to both LXRs. The EC 50 for paxilline-mediated LXR␣ recruitment of SRC-1 was 1,800 nM [22(R)-OHC ϭ 2,600 nM] whereas TIF-2 was 660 nM [22(R)-OHC ϭ 1,400 nM]. The EC 50 for paxilline-mediated LXR␤ recruitment of SRC-1 was 930 nM [22(R)-OHC ϭ 300 nM] whereas TIF-2 was 1,200 nM [22(R)-OHC ϭ 780 nM]. The ability of paxilline to induce coactivator recruitment by LXR suggested that paxilline might function as an agonist. This was confirmed in a transfection experiment in which HEK293 cells were cotransfected with either LXR␣ or LXR␤ and a reporter containing three copies of a DR4 element derived from the ABCA1 promoter (Fig. 4) . Paxilline activated transcription of both LXR␣ and LXR␤ with equivalent potency and efficacy as 22(R)-OHC (EC 50 ϳ 4,000 nM for both receptors and ligands). The apparent discrepancy between the affinity of 22(R)-OHC for LXR in the binding assay and the potency in a cotransfection assay has been previously described and is apparently a function of the physiochemical properties of this compound (Janowski et al., 1999) . Interestingly, paxilline functions as a partial agonist in the coactivator interaction assay [60 -90% 22(R)-OHC] but as a full agonist in the cotransfection assays. This suggests that either additional coactivators are recruited in the cellbased assay that allow for retention of full efficacy or that only a threshold of coactivator recruitment is required to reach full agonism. Consistent with its function as an agonist in both the coactivator recruitment and cotransfection assay, paxilline induced the expression of ABCA1 in THP-1 cells very efficaciously with a maximal induction of approximately 7-fold (EC 50 ϭ 1,300 nM) (Fig. 5) . In this paradigm, the dose A Natural Product Ligand of LXR response for 22(R)-OHC was limited by toxicity above 10 M; however, the potency is greater than 5,000 nM and the maximal efficacy at 10 M is approximately 6-fold. Paxilline also increased the expression of a second LXR target gene, SREBP, in HepG2 cells (Fig. 6A) . We used a SREBP-responsive luciferase reporter stably transfected into HepG2 cells (Thomas et al., 2003) to investigate the dose-responsiveness Utilizing Alpha-Screen technology, we evaluated whether paxilline would recruit coactivators (SRC-1 or TIF-2) to either LXR subtype in a biochemical model. Recombinant LXRs were attached to the donor bead via His-tagged Ni 2ϩ ion interaction while GST-fusion coactivators were attached to acceptor beads via a GST-Ab. Paxilline treatment resulted in dose-dependent recruitment of coactivators to either receptor subtype. For paxilline, the EC 50 for recruitment of SRC-1 and TIF-2 to LXR␣ was 1,800 and 660 nM, respectively. The EC 50 for recruitment of SRC-1 and TIF-2 to LXR␤ was 930 and 1,200 nM, respectively. For the natural LXR ligand, 22(R)-OHC, the EC 50 for recruitment of SRC-1 and TIF-2 to LXR␣ was 2,600 and 1,400 nM, respectively. The EC for recruitment of SRC-1 and TIF-1 to LXR␤ was 300 and 780 nM, respectively. In all cases, paxilline appears to have partial agonist activity compared with 22(R)-OHC with maximal efficacies ranging from 60 to 90% of 22(R)-OHC levels. THP-1 cells were differentiated as described under Materials and Methods followed by treatment with either paxilline or 22(R)-OHC for 24 h. After this treatment, the cells were harvested and ABCA1 mRNA levels were assessed by bDNA measurement. Paxilline stimulated ABCA1 mRNA expression approximately 7.5-fold with an EC 50 of 1,300 nM. 22(R)-OHC was less potent with an EC 50 of greater than 5,000 nM, and maximal efficacy was not measured due to limiting toxicity.
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of paxilline induction of SREBP expression. As illustrated in Fig. 6B , paxilline efficiently increased transcription from the SRE reporter with an EC 50 of 2,800 nM. These data demonstrate that paxilline binds directly to both LXR␣ and LXR␤, functions as an agonist with the ability to mediate recruitment of coactivators to the receptors, and activates transcription of a reporter gene as well as two natural LXR target genes.
Discussion
Since the identification of LXRs as orphan members of the nuclear hormone receptor superfamily in the mid-1990s, several ligands both natural and synthetic have been identified. Endogenous oxysterols were the first ligands identified for LXR, which suggested a role for this receptor in regulation of cholesterol homeostasis via action as a "cholesterol sensor" (Janowski et al., 1996) . The first target gene identified for LXR, cholesterol 7␣-hydroxylase (CYP7A), was consistent with this suggestion, illustrating a role for this receptor in regulation of the rate-limiting step in the conversion of cholesterol to bile acids (Lehmann et al., 1997) , which was later confirmed in the LXR null mouse (Peet et al., 1998) . In addition to its function in regulation of CYP7A, which appears to be rodent-specific, an array of additional target genes have been identified that establish LXR as a key regulator of cholesterol homeostasis. These genes include sterol transporters such as ABCA1, ABCG1, ABCG5, and ABCG8, as well as other genes demonstrated to be critical in lipid metabolism including apoE, apoCII, lipoprotein lipase, phospholipid transfer protein, and cholesterol ester transfer protein (Luo and Tall, 2000; Repa et al., 2000 Venkateswaran et al., 2000; Laffitte et al., 2001; Zhang et al., 2001; Cao et al., 2002; Mak et al., 2002) . The manner in which LXR regulates these genes suggests that activation of this receptor may be antiatherogenic, which has been confirmed in mouse models Tangirala et al., 2002) . The therapeutic potential of a LXR agonist has recently expanded by the demonstration that activation of this receptor results in both anti-inflammatory and antidiabetic activity by regulating an array of genes involved in either inflammatory processes or gluconeogenesis, respectively Fowler et al., 2003; Joseph et al., 2003) .
Development of selective, high-affinity ligands for LXR such as T1317 and GW3965 has proven to provide essential tools in characterization of the physiological and pathophysiological roles of LXR. In this study, we identified and characterized an additional ligand of LXR, which represents the first nonoxysterol natural product ligand for this receptor. Natural products have proven to be an abundant source of agents for pharmacological characterization of biomolecules as well as for medicinal purposes. Although natural product libraries have not been as profitable for identification of ligands for nuclear hormone receptors as they have been for other fields, such as ion channel pharmacology, key ligands have been identified in the past that target receptors such as ER, FXR, PXR, and peroxisome proliferator-activated receptor ␥. We identified paxilline, an indole alkoid fungal metabolite from P. paxilli, as an efficacious LXR agonist. Paxilline binds directly to both LXR␣ and LXR␤ resulting in coactivator recruitment and activation of LXR-dependent gene transcription. Paxilline exhibits similar potency and efficacy as the natural ligand, 22(R)-OHC, in cotransfection assays and in terms of induction of expression of a natural target gene, ABCA1. Additional pharmacological activities of paxilline precluded examination of modulation of LXR activity in vivo due to toxicity. Paxilline is a tremorgenic mycotoxin that is a well characterized antagonist of high conductance calciumactivated K channels (BK channel) with potencies in the range of 100 nM, which is clearly greater than the potencies we detected for the LXRs in the low single digit micromolar range (Knaus et al., 1994) .
Given the limitations for evaluation of paxilline in vivo, this compound still provides an additional tool for pharmacological characterization of LXR. In addition, the novel chemical structure provides insight into the diversity of chemical structures that can recognize the ligand binding pockets of both LXR␣ and LXR␤ leading to coactivator recruitment and transcriptional activation. Furthermore, identification of an additional natural product ligand for a nuclear hormone receptor indicates that natural product libraries may be a rich source for ligands of additional nuclear hormone receptors including the orphans. A, HepG2 cells were treated for 24 h with either 100 nM T1317 or various concentrations of paxilline for 24 h before lysis of the cells, preparation of total RNA, and quantitation of SREBP mRNA by real-time polymerase chain reaction as previously described (Thomas et al., 2003) . Paxilline dose dependently increased SREBP expression. B, HepG2 cells stably transfected with a SRE reporter construct were treated with various concentrations of paxilline to assess the ability of this ligand to induce SREBP. Paxilline increased reporter expression dose dependently displaying an EC 50 of 2,800 nM.
